Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Non-Current Assets for 7 consecutive years, with $31.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 10.17% to $31.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.3 million through Dec 2025, up 142.72% year-over-year, with the annual reading at $31.5 million for FY2025, 10.17% down from the prior year.
  • Non-Current Assets hit $31.5 million in Q4 2025 for Eton Pharmaceuticals, down from $32.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $35.1 million in Q4 2024 to a low of $743000.0 in Q3 2021.
  • Historically, Non-Current Assets has averaged $11.4 million across 5 years, with a median of $5.0 million in 2022.
  • Biggest five-year swings in Non-Current Assets: plummeted 53.85% in 2021 and later soared 616.22% in 2024.
  • Year by year, Non-Current Assets stood at $3.9 million in 2021, then soared by 30.17% to $5.0 million in 2022, then decreased by 2.49% to $4.9 million in 2023, then skyrocketed by 616.22% to $35.1 million in 2024, then decreased by 10.17% to $31.5 million in 2025.
  • Business Quant data shows Non-Current Assets for ETON at $31.5 million in Q4 2025, $32.5 million in Q3 2025, and $33.2 million in Q2 2025.